Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 23, 2024
Finance
Latest Jeito bet positions European VC for fourth exit
Mega-round for Alentis spotlights French firm’s investment style
BioCentury | May 26, 2023
Data Byte
The 20 biggest venture raises year-to-date: genetic medicines dominate
Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines
BioCentury | Apr 13, 2023
Finance
With interest high in Claudin pathway, Jeito backs Alentis’ dual clinical track
$105M series C round gives CLDN1-focused biotech ample cash to start Phase II trial in fibrosis, first-in-human cancer study
BioCentury | Dec 23, 2022
Discovery & Translation
Enhancer elements for tissue regeneration; plus Alentis’ mAb for fibrosis and more
BioCentury’s roundup of translational news
BioCentury | Jun 15, 2021
Finance
June 15 Quick Takes: $210M series B for Umoja; plus RayzeBio, Alentis, CRISPR-Capsida and more
The $210 million series B round for Umoja Biopharma Inc. is evidence that the concept of in vivo immune cell reprogramming is gaining steam. The company will use the funding to advance into the clinic
BioCentury | Nov 7, 2011
Finance
Verastem very aggressive
Westphal's preclinical cancer play Verastem files for $50M IPO
BioCentury | Aug 15, 2011
Emerging Company Profile
Verastem: Cancer stem cell engine
Verastem removes bottleneck to finding drug compounds against cancer stem cells
Items per page:
1 - 10 of 13